Federico Pérez Manghi

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Guillermo E. Umpierrez, Santiago Tofé, Federico Pérez Manghi et al. · Diabetes Care · 2014 · 323 citations

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes

Ildiko Lingvay, Federico Pérez Manghi, Pedro Alberto García-Hernández et al. · JAMA · 2016 · 208 citations

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes ( <scp>AWARD</scp> ‐8)

Kathleen Dungan, Raimund Weitgasser, Federico Pérez Manghi et al. · Diabetes Obesity and Metabolism · 2016 · 95 citations · Full text

Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study

Stephen A. Harrison, Federico Pérez Manghi, William B. Smith et al. · Nature Medicine · 2022 · 66 citations · Full text

Hepatology, Medicine, Nonalcoholic Steatohepatitis +3